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Edited by Veli-Pekka LehtoAbstract Recent studies implicate the collagen receptor, gly-
coprotein VI (GPVI) in activation of platelet 12-lipoxygenase
(p12-LOX). Herein, we show that GPVI-stimulated 12-hy-
dro(peroxy)eicosatetraenoic acid (H(P)ETE) synthesis is
inhibited by palmityl triﬂuromethyl ketone or ole-
yloxyethylphosphocholine , but not bromoenol lactone, implicat-
ing secretory and cytosolic, but not calcium-independent
phospholipase A2 (PLA2) isoforms. Also, following GPVI
activation, 12-LOX co-immunoprecipitates with both cytosolic
and secretory PLA2 (sPLA2). Finally, venoms containing sPLA2
acutely activate p12-LOX in a dose-dependent manner. This
study shows that platelet 12-H(P)ETE generation utilizes
arachidonate substrate from both c- and sPLA2 and that 12-
LOX functionally associates with both PLA2 isoforms.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Lipoxygenases (LOX) play central roles in vascular disease
via synthesis of hydro(peroxy)eicosatetraenoic acids (H(P)-
ETEs) from unsaturated fatty acids [1]. Currently, little is
known regarding acute control of LOX turnover in mamma-
lian cells. Activation has been previously reported for neu-
trophil 5-LOX by fMLP, and platelet 12-LOX (p12-LOX) in
platelets by collagen, and we recently reported that the colla-
gen receptor, glycoprotein VI (GPVI), activates p12-LOX in
platelets via src tyrosine kinases, PI3 kinase and calcium mo-
bilization [2–6]. Direct activation of cellular LOXs is thought
to involve (i) oxidation of the ferrous iron and (ii) transloca-
tion of the cytosolic enzyme to plasma or nuclear membranes.
In addition, provision of arachidonate substrate by phospho-
lipase A2 (PLA2) isoforms is a critical determinant of
H(P)ETE synthesis, especially for the p12-LOX isoform which
is unable to directly oxidize AA that is esteriﬁed to membrane
phospholipids. Several PLA2 isoforms are expressed by
mammalian cells and previous studies have found a role for* Corresponding author. Fax: +44-292074-8316.
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doi:10.1016/j.febslet.2004.09.007cytosolic calcium dependent PLA2 (cPLA2) in supply of ara-
chidonate to the 5-LOX isoform [7]. However, the source(s) of
arachidonate substrate for the p12-LOX and its interactions
with PLA2 isoforms following GPVI activation have not been
explored.
Platelets possess several PLA2 isoforms, including cPLA2,
calcium-independent (iPLA2) and group II secretory phos-
pholipase A2 (sPLA2) [8–10]. Studies on the mechanism of
GPVI-mediated activation of platelet 12-H(P)ETE synthesis
were undertaken to determine which of these PLA2 isoforms
are responsible for provision of arachidonate to platelet 12-
LOX. The study shows that GPVI-dependent 12-H(P)ETE
generation requires s- and cPLA2 isoforms, and that following
collagen or CRP activation, 12-LOX co-immunoprecipitates
with both isoforms. Finally, sPLA2 isoforms puriﬁed from
Apis mellifera or Bungarus multicinctus acutely stimulated 12-
H(P)ETE synthesis in a dose-dependent manner, indicating
that exogenous sPLA2 could also activate 12-LOX product
generation.2. Materials and methods
2.1. Reagents
Collagen (Type I) was from Mascia Brunelli, Milan, Italy. Collagen
related peptide (CRP) was synthesized to a known sequence [11].
12-Hydroxyeicosatetraenoic acid (12-HETE), 15-hydroxy-11Z,13E-
eicosadienoic acid (15-HEDE), bromoenol lactone (BEL), palmityl
triﬂuromethyl ketone (PACOCF3), oleyloxyethyl phosphorylcholine
(OOEPC), sPLA2 from Apis mellifera (>98% pure), b-bungarotoxin
sPLA2 from Bungarus multicinctus (>98% pure) and anti-sPLA2 IgG
were from Alexis Chemicals Ltd., Nottingham, UK. Anti-cPLA2 IgG
was from AbCam Ltd., Cambridge, UK. Anti-p12-LOX IgG was from
Oxford Biomedical Ltd., USA. All other reagents were from Sigma
Ltd., Poole, UK unless otherwise stated.
2.2. Preparation and activation of washed human platelets
Platelets were isolated as described [12] from consenting donors who
were NSAID-free for two weeks prior to donating. Washed platelets
were resuspended in Ca2þ-free Tyrodes buﬀer (134 mM NaCl, 12 mM
NaHCO3, 2.9 mM KCl, 0.34 mM Na2HPO4, 1 mM MgCl2, 10 mM
HEPES, and 5 mM glucose, pH 7.4). 3 108 platelets in 100 ll Ty-
rodes, 1 mM CaCl2, were stimulated with collagen (10 lgml1), CRP
(5–10 lgml1), bee sPLA2 (0–50 ngml1) or snake sPLA2 (0–10
lgml1) at 37 C with agitation for 10 min. Experiments using PLA2
inhibitors included a 10 min pre-incubation step at 37 C prior to
addition of agonist. Incubations were stopped by addition of 200 ll
ice-cold methanol and samples spun at 10 000· g for 10 min at 4 C.
Supernatants containing 12-H(P)ETE were recovered and supple-
mented with 200 ng 15(S)-HEDE per sample as an internal standard.blished by Elsevier B.V. All rights reserved.
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166 M.J. Coﬀey et al. / FEBS Letters 576 (2004) 165–1682.3. Reverse phase HPLC analysis of platelet 12-LOX products
Samples (equivalent to 2 107 cells) were separated on a 150
mm 4.6 mm, 5 m C18 ODS2 (Waters Ltd., Ireland) column using 50–
90% B over 20 min (A¼water:acetonitrile:acetic acid, 75:25:0.1,
B¼methanol:acetonitrile:acetic acid, 60:40:0.1) at 1 mlmin1. Ab-
sorbance was monitored at 235 nm. Products were identiﬁed and
quantiﬁed using 200 ng 12(S)-HETE standard run in parallel under the
same conditions.
2.4. Immunoprecipitation and Western blotting
Washed platelets (3 108 in 100 ll Tyrodes, pH 7.4, containing
1 mM CaCl2) treated with agonists and/or inhibitors at 37 C for 10
min with agitation were lyzed by resuspension in modiﬁed RIPA buﬀer
(1% (v/v) nonidet P40, 0.1% (w/v) SDS, 0.1% (w/v) sodium deoxy-
cholate, and PBS, pH 7.4) containing protease inhibitors at 4 C, at a
concentration of 1.5 109 cells/ml, and passing through a 21-gauge
needle twice, before addition of anti-c- or sPLA2 antibodies,
SDS–PAGE and immunoblotting (probing for p12-LOX) according to
existing protocols [13–15].
2.5. Statistical analysis
Data are representative of at least three separate donors, with
samples run in triplicate for each donor (means S.E.M.). Signiﬁcance
was examined using unpaired t test at the 95% conﬁdence interval,
where P 6 0:05 was considered signiﬁcant (denoted by ‘*’ in ﬁgures).
Activity in the presence of inhibitors is expressed as % relative to the
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Fig. 1. Collagen and CRP-mediated p12-LOX activity is sensitive to c-
and sPLA2 inhibition. Samples were analyzed for 12-H(P)ETE content
as described. Platelets were pre-incubated with the iPLA2 inhibitor
BEL (50 nM); the cPLA2 inhibitor PACOCF3 (10 lM) or the sPLA2
inhibitor OOEPC (2 lM) before adding collagen (10 lgml1) or CRP
(10 lgml1). (A) Inhibition of collagen-mediated p12-LOX by PLA2
inhibitors. Platelets + (a) collagen; (b) + collagen+BEL; (c) + colla-
gen+PACOCF3; (d) + collagen+OOEPC. (B) Inhibition of CRP-
mediated p12-LOX activity by PLA2 inhibitors. Platelets + (a) CRP;
(b) +CRP+BEL; (c) +CRP+PACOCF3; (d) +CRP+OOEPC.
Fig. 2. Platelet 12-LOX co-immunoprecipitates with cPLA2 and sPLA2
in agonist-treated washed platelets. (A) p12-LOX co-precipitates with
cPLA2 in agonist-treated washed platelets. Western blot probing for
p12-LOX following immunoprecipitation with anti-cPLA2 (a) un-
treated plateles; (b) +CRP (5 lgml1); (c) + collagen (10 lgml1). (B)
p12-LOX co-precipitates with sPLA2 in agonist-treated washed
platelets. Western blots probing for p12-LOX following immunopre-
cipitation with anti-sPLA2 (a) untreated platelets; (b) +CRP (5
lgml1); (c) + collagen (10 lgml1).3. Results
3.1. GPVI-mediated p12-LOX activity is sensitive to PLA2
inhibition
To determine which PLA2 isoforms provide arachidonate
substrate to 12-LOX following its activation by GPVI, plate-
lets were preincubated with inhibitors selective for particular
PLA2 isoforms and generation of 12-H(P)ETE in response to
collagen or CRP determined. Inclusion of BEL, which is se-
lective for iPLA2, was without eﬀect on either collagen or CRP
activation of 12-LOX ruling out a role for this isoform (up to
500 nM, Fig. 1 and data not shown). In contrast, 12H(P)ETE
synthesis was sensitive to inhibitors of c- or sPLA2, although
to diﬀerent extents depending on the agonist. In particular,
collagen activation was approximately 80% inhibited by PA-
COCF3, but only approximately 35% by OOEPC, whereas
CRP activation was inhibited 60% by OOEPC, but only 30%
by PACOCF3 (Fig. 1). This indicates that cPLA2 may be the
predominant source of arachidonate for p12-LOX in collagen-
activated platelets, whereas both cPLA2 and sPLA2 appear
important when selectively activating via GPVI.
3.2. Platelet 12-LOX co-immunoprecipitates with intracellular
PLA2 isoforms in agonist-treated washed platelets
To examine whether p12-LOX co-localizes with PLA2 iso-
forms following activation, human platelets were treated with
collagen or CRP before being subjected to immunoprecipita-
tion with anti-cPLA2 or anti-sPLA2 and then probing for p12-
LOX. Some immunoreactivity was observed in untreated
platelets indicating basal association, however, this was sub-
stantially increased following collagen or CRP activation of
platelets (Fig. 2A and B).
3.3. Venom sPLA2 acutely activates p12-LOX
To examine whether exogenous sPLA2 can activate p12-
LOX, sPLA2s from Apis mellifera (bee) or Bungarus multi-
cinctus (snake) were added to platelets and 12-H(P)ETE
generation determined. Both sPLA2 isoforms acutely activated
CRP     1       5      10     20     50
20
10
0
15
5
n
g 
12
-H
(P
)E
TE
 / 2
 x 
10
8
ce
lls
bee sPLA2 (ng.ml-1)
n
g 
12
-H
(P
)E
TE
 / 2
 x 
10
8
ce
lls
snake sPLA2 (µg.ml-1)
0.1      1.0     2.0       5.0     10.0
5
4
3
2
1
0
5 µg.ml-1
A
B
Fig. 3. Platelet 12-LOX is activated in a dose-dependent manner by bee
and snake venom sPLA2. (A) Dose-dependent activation of p12-LOX
by bee venom sPLA2. 3 108 platelets in Tyrodes buﬀer (pH 7.4),
1 mM CaCl2 were treated with sPLA2 (1–50 ngml
1), or CRP
(5 lgml1) as described in Section 2. (B) Dose-dependent activation of
p12-LOX by snake venom sPLA2. 3 108 platelets in Tyrodes buﬀer
(pH 7.4), 1 mM CaCl2 were activated with sPLA2 (0.1–10 gml
1).
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(18.87 2.00 and 6.85 0.96 ng/2 108 platelets, for bee and
snake isoforms, respectively, mean S.D., n ¼ 3, Fig. 3A and
B). In contrast, bovine pancreatic sPLA2 was unable to stim-
ulate generation of p12-LOX products (not shown). These
data indicate that exogenous sPLA2 isoforms can also activate
p12-LOX, in addition to platelet sPLA2.4. Discussion
The detailed signaling pathways that activate LOX turnover
and H(P)ETE synthesis acutely in mammalian cells are only
now being characterized. We recently found a role for the
collagen receptor, GPVI, in mediating acute activation of the
platelet 12-LOX isoform and demonstrated a role for several
downstream intracellular signaling pathways, including src
tyrosine kinases, calcium mobilization and PI3 kinase [2], whilea separate study found that collagen-induced arachidonate
release requires H2O2 generation [16]. The present study fur-
ther characterizes the pathway of GPVI activation of p12-
LOX, with particular regard to which PLA2 isoforms provide
p12-LOX with arachidonate. Use of pharmacological inhibi-
tors demonstrated that iPLA2 is not involved in this pathway
(Fig. 1). In contrast, both c- and sPLA2 were required for full
12-LOX turnover (Fig. 1). Further evidence for their involve-
ment was provided by immunoprecipitation experiments that
demonstrated that either PLA2 isoform was associated with
p12-LOX following activation with collagen or CRP (Fig. 2).
Previous studies have suggested that cPLA2 is an important
source of arachidonate for the 5-LOX and 12/15-LOX iso-
forms [7,17], but investigations into associations of cPLA2
with platelet 12-LOX have not been carried out. Our obser-
vations suggest a critical role for cPLA2 in providing substrate
to the p12-LOX also. This is in agreement with a recent study
which showed that deletion of cPLA2 causes 80% reduction in
serum 12-HETE levels, although in mice this metabolite will
not exclusively originate from platelet 12-LOX, as 12/15-LOX
will also be a signiﬁcant source [18].
A role for sPLA2 in providing arachidonate for 12-H(P)ETE
generation was also found, indicating that this isoform may be
functionally coupled to p12-LOX following GPVI activation
in platelets. To our knowledge, this is the ﬁrst report of sPLA2
involvement in GPVI signaling. Previous reports have shown
that 12-H(P)ETE generated by leukocyte-type 12/15-LOX
(following provision of substrate by cPLA2) can activate
sPLA2 to release more AA, which is in turn metabolized to
H(P)ETE by 12/15-LOX [17,19]. This was proposed to mediate
a paracrine ampliﬁcation of inﬂammation and showed a
pathway, whereby cPLA2 can activate sPLA2 during cell sig-
naling [20,21]. It is possible that a similar mechanism also
exists in platelets since (i) exogenously added platelet-derived
sPLA2 is unable to mobilize arachidonate from resting plate-
lets and (ii) addition of lipid hydroperoxide to rabbit platelets
can overcome the inability of exogenous group II sPLA2 to
hydrolyze platelet membrane phospholipids [9,22]. The relative
involvement of c- or sPLA2 in 12-H(P)ETE synthesis varied
with agonist used, with cPLA2 being the predominant ara-
chidonate source in collagen-activated platelets, and both
cPLA2 and sPLA2 being similarly involved when selectively
activating GPVI (Fig. 1). This diﬀerence may reﬂect signaling
via additional receptors when using collagen as agonist, in-
cluding a(IIb)b(3) integrin which can also activate thrombox-
ane generation [23].
Our observation of co-precipitation of p12-LOX with sPLA2
suggests that these enzymes are localized together during 12-
H(P)ETE synthesis. Previous studies have shown that several
sPLA2 isoforms act internally to release arachidonate. For
example, group IV sPLA2 acts on the perinuclear membrane,
where it co-localizes with 5-LOX [24]. Additionally, sPLA2-
IIA is sorted into caveolin-rich vesicular and perinuclear
compartments during its secretion and internalization through
association with glypican, a GPI-linked form of heparan sul-
fate proteoglycan [25]. Finally, sPLA2-IIF localizes to the
plasma membrane in HEK293 cells, and is coupled to down-
stream synthesis of both cyclooxygenase and 5-LOX inde-
pendently of glypican [26].
Finally, we found that bee or snake venom sPLA2, but not
bovine pancreatic sPLA2 could acutely activate 12-H(P)ETE
generation in platelets. This is similar to previous observations
168 M.J. Coﬀey et al. / FEBS Letters 576 (2004) 165–168that bovine pancreatic or platelet sPLA2s do not activate
platelets, unlike venom isoforms, and has been suggested to be
related to both origin (venom versus mammalian) and the
relative inability of mammalian isoforms to hydrolyze phos-
phatidylcholine, the major phospholipid of the outer leaﬂet of
the plasma membrane, in the absence of cPLA2 turnover
[9,17,20,27].
The biological signiﬁcance of p12-LOX remains unknown,
but a pathophysiological involvement in autoimmune throm-
bocytopaenia was recently suggested [28]. Herein, sPLA2 was
utilized as a tool for dissecting LOX activation mechanisms,
however, following exposure to venom sPLA2 through bites or
stings, it is possible that p12-LOX product generation may
play a role in the thrombocytopaenia which can result [29].
In summary, this study shows that c- and sPLA2 isoforms
associate with and provide substrate to p12-LOX following
activation of platelets by the collagen receptor GPVI and
demonstrates a signiﬁcant involvement of sPLA2 in collagen
signaling in platelets.
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